A novel augmentation strategy for treating resistant major depression

American Journal of Psychiatry

Volumn 158, Issue 1, 2001, Pages 131-134

  Shelton, R C ^a   Tollefson, G D ^a   Tohen, M ^a   Stahl, S ^a   Gannon, K S ^a   Jacobs, T G ^a   Buras, W R ^a   Bymaster, F P ^a   Zhang, W ^a   Spencer, K A ^a   Feldman, P D ^a   Meltzer, H Y ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; OLANZAPINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AMBULATORY CARE; BASAL GANGLIA DISEASES; BENZODIAZEPINES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; PIRENZEPINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0035169876     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.1.131     Document Type: Article

References (24)

1. Treatment algorithms in treatment-resistant depression
2. Progress in treatment-resistant and treatment-refractory depression: We still have a long way to go
3. Treatment-resistant depression: Definition and treatment approaches
4. Tricyclic nonresponders: Phenomenology and treatment
5. Major tranquillisers used as antidepressants: A review
6. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression
7. The pharmacological treatment of delusional depression
8. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: Observation of clinical use
9. Pharmacotherapy of delusional depression: Experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol
10. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia
11. Tardive dyskinesia
12. Extrapyramidal symptoms and tolerabitity of olanzapine versus haloperidol in the acute treatment of schizophrenia
13. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
14. A rating scale for depression
15. The application of the principle of intention-to-treat to the analysis of clinical trials
16. A new depression scale designed to be sensitive to change
17. Radioreceptor binding profile of the atypical antipsychotic olanzapine
18. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
19. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
20. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
21. Dopamine, the prefrontal cortex and schizophrenia
22. Dopaminergic mechanisms in depression and mania
23. Recent studies on norepinephrine systems in mood disorders